Core Viewpoint - Heptagon Pharmaceuticals-B (02142) is planning to repurchase shares worth up to HKD 300 million, following approval from shareholders at the upcoming annual general meeting in June 2025, while also making significant advancements in its AI drug development business [1][1][1] Group 1: Share Repurchase Announcement - Heptagon Pharmaceuticals-B announced a share repurchase plan not exceeding HKD 300 million, subject to shareholder approval at the annual general meeting on June 11, 2025 [1] - The company's stock price increased by over 3%, currently trading at HKD 12.18 with a trading volume of HKD 14.03 million [1] Group 2: AI Drug Development Progress - Heptagon Pharmaceuticals-B has introduced recent developments in its AI drug business, including the launch of the Hu-mAtrIx™ AI platform [1] - The company has established the first fully human AI HCAb model, focusing on generating and screening fully human heavy-chain antibodies [1] - The strategic integration of antibody engineering, AI-assisted drug discovery, and automated wet laboratories forms the A3 macromolecule innovative drug R&D platform, creating a feedback loop for high-quality AI model training [1]
港股异动 | 和铂医药-B(02142)涨超3% 公司拟回购不超过3亿港元股份 将加大发展AI智药战略